Real-world experience with pembrolizumab toxicities in advanced melanoma patients: a single-center experience in the UK
Aim: We aimed to characterize the safety profile of pembrolizumab in advanced melanoma patients at our center to better reflect ‘real-world’ data on anti-PD-1 inhibitors. Materials & methods: At our institution, 58 ipilimumab-naive and 30 ipilimumab-treated patients with advanced melanoma who ha...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2018-03-01
|
| Series: | Melanoma Management |
| Subjects: | |
| Online Access: | https://www.futuremedicine.com/doi/10.2217/mmt-2017-0028 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|